NRx Pharmaceuticals receives QIDP, fast track designation from FDA for NRX-101

NRx Pharmaceuticals announced that it has received Qualified Infectious Disease Product, or QIDP, and fast track designation from the FDA for NRX-101 in the treatment of complicated urinary tract infections, or cUTI, and pyelonephritis. Receipt of QIDP designation confers priority review, and five additional years of data-exclusivity to NRX-101’s intellectual property position.